nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadopentetate dimeglumine—PGD—Methotrexate—urinary bladder cancer	0.69	1	CbGbCtD
Gadopentetate dimeglumine—PGD—prostate gland—urinary bladder cancer	0.00662	0.19	CbGeAlD
Gadopentetate dimeglumine—PGD—seminal vesicle—urinary bladder cancer	0.0056	0.161	CbGeAlD
Gadopentetate dimeglumine—PGD—smooth muscle tissue—urinary bladder cancer	0.00468	0.135	CbGeAlD
Gadopentetate dimeglumine—PGD—renal system—urinary bladder cancer	0.00451	0.13	CbGeAlD
Gadopentetate dimeglumine—PGD—urethra—urinary bladder cancer	0.00443	0.127	CbGeAlD
Gadopentetate dimeglumine—PGD—female reproductive system—urinary bladder cancer	0.00361	0.104	CbGeAlD
Gadopentetate dimeglumine—PGD—vagina—urinary bladder cancer	0.00327	0.0938	CbGeAlD
Gadopentetate dimeglumine—PGD—lymph node—urinary bladder cancer	0.00211	0.0607	CbGeAlD
Gadopentetate dimeglumine—Dyspnoea—Etoposide—urinary bladder cancer	0.00022	0.0008	CcSEcCtD
Gadopentetate dimeglumine—Somnolence—Etoposide—urinary bladder cancer	0.000219	0.000798	CcSEcCtD
Gadopentetate dimeglumine—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000219	0.000797	CcSEcCtD
Gadopentetate dimeglumine—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000219	0.000797	CcSEcCtD
Gadopentetate dimeglumine—Vomiting—Thiotepa—urinary bladder cancer	0.000219	0.000794	CcSEcCtD
Gadopentetate dimeglumine—Drowsiness—Epirubicin—urinary bladder cancer	0.000217	0.000789	CcSEcCtD
Gadopentetate dimeglumine—Rash—Thiotepa—urinary bladder cancer	0.000217	0.000787	CcSEcCtD
Gadopentetate dimeglumine—Dermatitis—Thiotepa—urinary bladder cancer	0.000216	0.000787	CcSEcCtD
Gadopentetate dimeglumine—Headache—Thiotepa—urinary bladder cancer	0.000215	0.000782	CcSEcCtD
Gadopentetate dimeglumine—Decreased appetite—Etoposide—urinary bladder cancer	0.000215	0.00078	CcSEcCtD
Gadopentetate dimeglumine—Renal failure—Epirubicin—urinary bladder cancer	0.000213	0.000775	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000213	0.000775	CcSEcCtD
Gadopentetate dimeglumine—Body temperature increased—Cisplatin—urinary bladder cancer	0.000213	0.000774	CcSEcCtD
Gadopentetate dimeglumine—Fatigue—Etoposide—urinary bladder cancer	0.000213	0.000773	CcSEcCtD
Gadopentetate dimeglumine—Pain—Etoposide—urinary bladder cancer	0.000211	0.000767	CcSEcCtD
Gadopentetate dimeglumine—Constipation—Etoposide—urinary bladder cancer	0.000211	0.000767	CcSEcCtD
Gadopentetate dimeglumine—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000211	0.000766	CcSEcCtD
Gadopentetate dimeglumine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000209	0.000761	CcSEcCtD
Gadopentetate dimeglumine—Sweating—Epirubicin—urinary bladder cancer	0.000208	0.000756	CcSEcCtD
Gadopentetate dimeglumine—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000208	0.000756	CcSEcCtD
Gadopentetate dimeglumine—Asthenia—Gemcitabine—urinary bladder cancer	0.000207	0.000754	CcSEcCtD
Gadopentetate dimeglumine—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000206	0.000747	CcSEcCtD
Gadopentetate dimeglumine—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000205	0.000746	CcSEcCtD
Gadopentetate dimeglumine—Pruritus—Gemcitabine—urinary bladder cancer	0.000205	0.000743	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Thiotepa—urinary bladder cancer	0.000204	0.000742	CcSEcCtD
Gadopentetate dimeglumine—Urethral disorder—Methotrexate—urinary bladder cancer	0.000204	0.000741	CcSEcCtD
Gadopentetate dimeglumine—Feeling abnormal—Etoposide—urinary bladder cancer	0.000203	0.000739	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000202	0.000734	CcSEcCtD
Gadopentetate dimeglumine—Pruritus—Fluorouracil—urinary bladder cancer	0.000201	0.000731	CcSEcCtD
Gadopentetate dimeglumine—Drowsiness—Doxorubicin—urinary bladder cancer	0.000201	0.00073	CcSEcCtD
Gadopentetate dimeglumine—Visual impairment—Methotrexate—urinary bladder cancer	0.000201	0.000729	CcSEcCtD
Gadopentetate dimeglumine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000199	0.000722	CcSEcCtD
Gadopentetate dimeglumine—Bradycardia—Epirubicin—urinary bladder cancer	0.000198	0.000721	CcSEcCtD
Gadopentetate dimeglumine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000198	0.000719	CcSEcCtD
Gadopentetate dimeglumine—Renal failure—Doxorubicin—urinary bladder cancer	0.000197	0.000717	CcSEcCtD
Gadopentetate dimeglumine—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000197	0.000715	CcSEcCtD
Gadopentetate dimeglumine—Urticaria—Etoposide—urinary bladder cancer	0.000196	0.000713	CcSEcCtD
Gadopentetate dimeglumine—Rhinitis—Epirubicin—urinary bladder cancer	0.000195	0.00071	CcSEcCtD
Gadopentetate dimeglumine—Abdominal pain—Etoposide—urinary bladder cancer	0.000195	0.000709	CcSEcCtD
Gadopentetate dimeglumine—Body temperature increased—Etoposide—urinary bladder cancer	0.000195	0.000709	CcSEcCtD
Gadopentetate dimeglumine—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000195	0.000709	CcSEcCtD
Gadopentetate dimeglumine—Eye disorder—Methotrexate—urinary bladder cancer	0.000195	0.000707	CcSEcCtD
Gadopentetate dimeglumine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000194	0.000707	CcSEcCtD
Gadopentetate dimeglumine—Tinnitus—Methotrexate—urinary bladder cancer	0.000194	0.000705	CcSEcCtD
Gadopentetate dimeglumine—Asthenia—Cisplatin—urinary bladder cancer	0.000193	0.000703	CcSEcCtD
Gadopentetate dimeglumine—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000193	0.000702	CcSEcCtD
Gadopentetate dimeglumine—Sweating—Doxorubicin—urinary bladder cancer	0.000192	0.000699	CcSEcCtD
Gadopentetate dimeglumine—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000192	0.000699	CcSEcCtD
Gadopentetate dimeglumine—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000192	0.000697	CcSEcCtD
Gadopentetate dimeglumine—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000191	0.000696	CcSEcCtD
Gadopentetate dimeglumine—Urethral disorder—Epirubicin—urinary bladder cancer	0.000191	0.000694	CcSEcCtD
Gadopentetate dimeglumine—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.00019	0.00069	CcSEcCtD
Gadopentetate dimeglumine—Angiopathy—Methotrexate—urinary bladder cancer	0.000189	0.000686	CcSEcCtD
Gadopentetate dimeglumine—Immune system disorder—Methotrexate—urinary bladder cancer	0.000188	0.000683	CcSEcCtD
Gadopentetate dimeglumine—Dizziness—Fluorouracil—urinary bladder cancer	0.000188	0.000683	CcSEcCtD
Gadopentetate dimeglumine—Visual impairment—Epirubicin—urinary bladder cancer	0.000188	0.000682	CcSEcCtD
Gadopentetate dimeglumine—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000188	0.000682	CcSEcCtD
Gadopentetate dimeglumine—Chills—Methotrexate—urinary bladder cancer	0.000187	0.000679	CcSEcCtD
Gadopentetate dimeglumine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000184	0.00067	CcSEcCtD
Gadopentetate dimeglumine—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000184	0.000669	CcSEcCtD
Gadopentetate dimeglumine—Vomiting—Gemcitabine—urinary bladder cancer	0.000184	0.000668	CcSEcCtD
Gadopentetate dimeglumine—Bradycardia—Doxorubicin—urinary bladder cancer	0.000183	0.000667	CcSEcCtD
Gadopentetate dimeglumine—Mental disorder—Methotrexate—urinary bladder cancer	0.000182	0.000663	CcSEcCtD
Gadopentetate dimeglumine—Rash—Gemcitabine—urinary bladder cancer	0.000182	0.000662	CcSEcCtD
Gadopentetate dimeglumine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000182	0.000662	CcSEcCtD
Gadopentetate dimeglumine—Eye disorder—Epirubicin—urinary bladder cancer	0.000182	0.000662	CcSEcCtD
Gadopentetate dimeglumine—Hypersensitivity—Etoposide—urinary bladder cancer	0.000182	0.000661	CcSEcCtD
Gadopentetate dimeglumine—Tinnitus—Epirubicin—urinary bladder cancer	0.000182	0.00066	CcSEcCtD
Gadopentetate dimeglumine—Erythema—Methotrexate—urinary bladder cancer	0.000181	0.000658	CcSEcCtD
Gadopentetate dimeglumine—Headache—Gemcitabine—urinary bladder cancer	0.000181	0.000658	CcSEcCtD
Gadopentetate dimeglumine—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000181	0.000657	CcSEcCtD
Gadopentetate dimeglumine—Flushing—Epirubicin—urinary bladder cancer	0.000181	0.000657	CcSEcCtD
Gadopentetate dimeglumine—Vomiting—Fluorouracil—urinary bladder cancer	0.000181	0.000657	CcSEcCtD
Gadopentetate dimeglumine—Rhinitis—Doxorubicin—urinary bladder cancer	0.000181	0.000657	CcSEcCtD
Gadopentetate dimeglumine—Rash—Fluorouracil—urinary bladder cancer	0.000179	0.000651	CcSEcCtD
Gadopentetate dimeglumine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000179	0.000651	CcSEcCtD
Gadopentetate dimeglumine—Headache—Fluorouracil—urinary bladder cancer	0.000178	0.000647	CcSEcCtD
Gadopentetate dimeglumine—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000178	0.000647	CcSEcCtD
Gadopentetate dimeglumine—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000178	0.000645	CcSEcCtD
Gadopentetate dimeglumine—Dysgeusia—Methotrexate—urinary bladder cancer	0.000177	0.000645	CcSEcCtD
Gadopentetate dimeglumine—Asthenia—Etoposide—urinary bladder cancer	0.000177	0.000644	CcSEcCtD
Gadopentetate dimeglumine—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000177	0.000644	CcSEcCtD
Gadopentetate dimeglumine—Angiopathy—Epirubicin—urinary bladder cancer	0.000177	0.000642	CcSEcCtD
Gadopentetate dimeglumine—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000177	0.000642	CcSEcCtD
Gadopentetate dimeglumine—Immune system disorder—Epirubicin—urinary bladder cancer	0.000176	0.000639	CcSEcCtD
Gadopentetate dimeglumine—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000176	0.000638	CcSEcCtD
Gadopentetate dimeglumine—Back pain—Methotrexate—urinary bladder cancer	0.000175	0.000637	CcSEcCtD
Gadopentetate dimeglumine—Chills—Epirubicin—urinary bladder cancer	0.000175	0.000635	CcSEcCtD
Gadopentetate dimeglumine—Pruritus—Etoposide—urinary bladder cancer	0.000175	0.000635	CcSEcCtD
Gadopentetate dimeglumine—Arrhythmia—Epirubicin—urinary bladder cancer	0.000174	0.000632	CcSEcCtD
Gadopentetate dimeglumine—Visual impairment—Doxorubicin—urinary bladder cancer	0.000174	0.000631	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Gemcitabine—urinary bladder cancer	0.000172	0.000624	CcSEcCtD
Gadopentetate dimeglumine—Vomiting—Cisplatin—urinary bladder cancer	0.000171	0.000623	CcSEcCtD
Gadopentetate dimeglumine—Mental disorder—Epirubicin—urinary bladder cancer	0.000171	0.00062	CcSEcCtD
Gadopentetate dimeglumine—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.00017	0.000619	CcSEcCtD
Gadopentetate dimeglumine—Rash—Cisplatin—urinary bladder cancer	0.00017	0.000617	CcSEcCtD
Gadopentetate dimeglumine—Dermatitis—Cisplatin—urinary bladder cancer	0.00017	0.000617	CcSEcCtD
Gadopentetate dimeglumine—Erythema—Epirubicin—urinary bladder cancer	0.00017	0.000616	CcSEcCtD
Gadopentetate dimeglumine—Diarrhoea—Etoposide—urinary bladder cancer	0.000169	0.000614	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Fluorouracil—urinary bladder cancer	0.000169	0.000614	CcSEcCtD
Gadopentetate dimeglumine—Eye disorder—Doxorubicin—urinary bladder cancer	0.000168	0.000612	CcSEcCtD
Gadopentetate dimeglumine—Tinnitus—Doxorubicin—urinary bladder cancer	0.000168	0.000611	CcSEcCtD
Gadopentetate dimeglumine—Flushing—Doxorubicin—urinary bladder cancer	0.000167	0.000608	CcSEcCtD
Gadopentetate dimeglumine—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000167	0.000608	CcSEcCtD
Gadopentetate dimeglumine—Tension—Epirubicin—urinary bladder cancer	0.000166	0.000605	CcSEcCtD
Gadopentetate dimeglumine—Dysgeusia—Epirubicin—urinary bladder cancer	0.000166	0.000603	CcSEcCtD
Gadopentetate dimeglumine—Back pain—Epirubicin—urinary bladder cancer	0.000164	0.000596	CcSEcCtD
Gadopentetate dimeglumine—Angiopathy—Doxorubicin—urinary bladder cancer	0.000164	0.000594	CcSEcCtD
Gadopentetate dimeglumine—Malaise—Methotrexate—urinary bladder cancer	0.000163	0.000594	CcSEcCtD
Gadopentetate dimeglumine—Dizziness—Etoposide—urinary bladder cancer	0.000163	0.000593	CcSEcCtD
Gadopentetate dimeglumine—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000163	0.000592	CcSEcCtD
Gadopentetate dimeglumine—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000162	0.00059	CcSEcCtD
Gadopentetate dimeglumine—Chills—Doxorubicin—urinary bladder cancer	0.000162	0.000588	CcSEcCtD
Gadopentetate dimeglumine—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000161	0.000585	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Cisplatin—urinary bladder cancer	0.00016	0.000582	CcSEcCtD
Gadopentetate dimeglumine—Cough—Methotrexate—urinary bladder cancer	0.000158	0.000575	CcSEcCtD
Gadopentetate dimeglumine—Mental disorder—Doxorubicin—urinary bladder cancer	0.000158	0.000574	CcSEcCtD
Gadopentetate dimeglumine—Convulsion—Methotrexate—urinary bladder cancer	0.000157	0.00057	CcSEcCtD
Gadopentetate dimeglumine—Vomiting—Etoposide—urinary bladder cancer	0.000157	0.00057	CcSEcCtD
Gadopentetate dimeglumine—Erythema—Doxorubicin—urinary bladder cancer	0.000157	0.00057	CcSEcCtD
Gadopentetate dimeglumine—Agitation—Epirubicin—urinary bladder cancer	0.000156	0.000566	CcSEcCtD
Gadopentetate dimeglumine—Rash—Etoposide—urinary bladder cancer	0.000156	0.000566	CcSEcCtD
Gadopentetate dimeglumine—Dermatitis—Etoposide—urinary bladder cancer	0.000156	0.000565	CcSEcCtD
Gadopentetate dimeglumine—Headache—Etoposide—urinary bladder cancer	0.000155	0.000562	CcSEcCtD
Gadopentetate dimeglumine—Chest pain—Methotrexate—urinary bladder cancer	0.000154	0.000561	CcSEcCtD
Gadopentetate dimeglumine—Arthralgia—Methotrexate—urinary bladder cancer	0.000154	0.000561	CcSEcCtD
Gadopentetate dimeglumine—Tension—Doxorubicin—urinary bladder cancer	0.000154	0.000559	CcSEcCtD
Gadopentetate dimeglumine—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000154	0.000558	CcSEcCtD
Gadopentetate dimeglumine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000153	0.000557	CcSEcCtD
Gadopentetate dimeglumine—Malaise—Epirubicin—urinary bladder cancer	0.000153	0.000556	CcSEcCtD
Gadopentetate dimeglumine—Syncope—Epirubicin—urinary bladder cancer	0.000152	0.000553	CcSEcCtD
Gadopentetate dimeglumine—Back pain—Doxorubicin—urinary bladder cancer	0.000152	0.000552	CcSEcCtD
Gadopentetate dimeglumine—Confusional state—Methotrexate—urinary bladder cancer	0.000149	0.000542	CcSEcCtD
Gadopentetate dimeglumine—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000149	0.000542	CcSEcCtD
Gadopentetate dimeglumine—Cough—Epirubicin—urinary bladder cancer	0.000148	0.000538	CcSEcCtD
Gadopentetate dimeglumine—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000148	0.000537	CcSEcCtD
Gadopentetate dimeglumine—Convulsion—Epirubicin—urinary bladder cancer	0.000147	0.000534	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Etoposide—urinary bladder cancer	0.000147	0.000533	CcSEcCtD
Gadopentetate dimeglumine—Hypertension—Epirubicin—urinary bladder cancer	0.000146	0.000532	CcSEcCtD
Gadopentetate dimeglumine—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000145	0.000527	CcSEcCtD
Gadopentetate dimeglumine—Arthralgia—Epirubicin—urinary bladder cancer	0.000144	0.000525	CcSEcCtD
Gadopentetate dimeglumine—Chest pain—Epirubicin—urinary bladder cancer	0.000144	0.000525	CcSEcCtD
Gadopentetate dimeglumine—Agitation—Doxorubicin—urinary bladder cancer	0.000144	0.000524	CcSEcCtD
Gadopentetate dimeglumine—Anxiety—Epirubicin—urinary bladder cancer	0.000144	0.000523	CcSEcCtD
Gadopentetate dimeglumine—Skin disorder—Methotrexate—urinary bladder cancer	0.000144	0.000522	CcSEcCtD
Gadopentetate dimeglumine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000143	0.000521	CcSEcCtD
Gadopentetate dimeglumine—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000143	0.00052	CcSEcCtD
Gadopentetate dimeglumine—Malaise—Doxorubicin—urinary bladder cancer	0.000141	0.000514	CcSEcCtD
Gadopentetate dimeglumine—Dry mouth—Epirubicin—urinary bladder cancer	0.000141	0.000513	CcSEcCtD
Gadopentetate dimeglumine—Anorexia—Methotrexate—urinary bladder cancer	0.000141	0.000512	CcSEcCtD
Gadopentetate dimeglumine—Syncope—Doxorubicin—urinary bladder cancer	0.000141	0.000511	CcSEcCtD
Gadopentetate dimeglumine—Confusional state—Epirubicin—urinary bladder cancer	0.00014	0.000507	CcSEcCtD
Gadopentetate dimeglumine—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000138	0.000503	CcSEcCtD
Gadopentetate dimeglumine—Hypotension—Methotrexate—urinary bladder cancer	0.000138	0.000502	CcSEcCtD
Gadopentetate dimeglumine—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000138	0.000501	CcSEcCtD
Gadopentetate dimeglumine—Cough—Doxorubicin—urinary bladder cancer	0.000137	0.000498	CcSEcCtD
Gadopentetate dimeglumine—Shock—Epirubicin—urinary bladder cancer	0.000136	0.000495	CcSEcCtD
Gadopentetate dimeglumine—Convulsion—Doxorubicin—urinary bladder cancer	0.000136	0.000494	CcSEcCtD
Gadopentetate dimeglumine—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000136	0.000493	CcSEcCtD
Gadopentetate dimeglumine—Hypertension—Doxorubicin—urinary bladder cancer	0.000135	0.000492	CcSEcCtD
Gadopentetate dimeglumine—Tachycardia—Epirubicin—urinary bladder cancer	0.000135	0.000491	CcSEcCtD
Gadopentetate dimeglumine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000135	0.00049	CcSEcCtD
Gadopentetate dimeglumine—Skin disorder—Epirubicin—urinary bladder cancer	0.000134	0.000488	CcSEcCtD
Gadopentetate dimeglumine—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000134	0.000486	CcSEcCtD
Gadopentetate dimeglumine—Chest pain—Doxorubicin—urinary bladder cancer	0.000134	0.000485	CcSEcCtD
Gadopentetate dimeglumine—Arthralgia—Doxorubicin—urinary bladder cancer	0.000134	0.000485	CcSEcCtD
Gadopentetate dimeglumine—Anxiety—Doxorubicin—urinary bladder cancer	0.000133	0.000484	CcSEcCtD
Gadopentetate dimeglumine—Paraesthesia—Methotrexate—urinary bladder cancer	0.000133	0.000483	CcSEcCtD
Gadopentetate dimeglumine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000133	0.000482	CcSEcCtD
Gadopentetate dimeglumine—Anorexia—Epirubicin—urinary bladder cancer	0.000132	0.000479	CcSEcCtD
Gadopentetate dimeglumine—Dyspnoea—Methotrexate—urinary bladder cancer	0.000132	0.000479	CcSEcCtD
Gadopentetate dimeglumine—Somnolence—Methotrexate—urinary bladder cancer	0.000131	0.000478	CcSEcCtD
Gadopentetate dimeglumine—Dry mouth—Doxorubicin—urinary bladder cancer	0.000131	0.000475	CcSEcCtD
Gadopentetate dimeglumine—Hypotension—Epirubicin—urinary bladder cancer	0.000129	0.00047	CcSEcCtD
Gadopentetate dimeglumine—Confusional state—Doxorubicin—urinary bladder cancer	0.000129	0.000469	CcSEcCtD
Gadopentetate dimeglumine—Decreased appetite—Methotrexate—urinary bladder cancer	0.000129	0.000467	CcSEcCtD
Gadopentetate dimeglumine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000128	0.000465	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000128	0.000464	CcSEcCtD
Gadopentetate dimeglumine—Fatigue—Methotrexate—urinary bladder cancer	0.000127	0.000463	CcSEcCtD
Gadopentetate dimeglumine—Pain—Methotrexate—urinary bladder cancer	0.000126	0.00046	CcSEcCtD
Gadopentetate dimeglumine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000126	0.000458	CcSEcCtD
Gadopentetate dimeglumine—Shock—Doxorubicin—urinary bladder cancer	0.000126	0.000458	CcSEcCtD
Gadopentetate dimeglumine—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000126	0.000456	CcSEcCtD
Gadopentetate dimeglumine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000125	0.000454	CcSEcCtD
Gadopentetate dimeglumine—Skin disorder—Doxorubicin—urinary bladder cancer	0.000124	0.000452	CcSEcCtD
Gadopentetate dimeglumine—Paraesthesia—Epirubicin—urinary bladder cancer	0.000124	0.000452	CcSEcCtD
Gadopentetate dimeglumine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000124	0.00045	CcSEcCtD
Gadopentetate dimeglumine—Dyspnoea—Epirubicin—urinary bladder cancer	0.000123	0.000448	CcSEcCtD
Gadopentetate dimeglumine—Somnolence—Epirubicin—urinary bladder cancer	0.000123	0.000447	CcSEcCtD
Gadopentetate dimeglumine—Anorexia—Doxorubicin—urinary bladder cancer	0.000122	0.000444	CcSEcCtD
Gadopentetate dimeglumine—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000122	0.000443	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000121	0.000439	CcSEcCtD
Gadopentetate dimeglumine—Decreased appetite—Epirubicin—urinary bladder cancer	0.00012	0.000437	CcSEcCtD
Gadopentetate dimeglumine—Hypotension—Doxorubicin—urinary bladder cancer	0.00012	0.000435	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000119	0.000434	CcSEcCtD
Gadopentetate dimeglumine—Fatigue—Epirubicin—urinary bladder cancer	0.000119	0.000434	CcSEcCtD
Gadopentetate dimeglumine—Pain—Epirubicin—urinary bladder cancer	0.000118	0.00043	CcSEcCtD
Gadopentetate dimeglumine—Constipation—Epirubicin—urinary bladder cancer	0.000118	0.00043	CcSEcCtD
Gadopentetate dimeglumine—Urticaria—Methotrexate—urinary bladder cancer	0.000117	0.000427	CcSEcCtD
Gadopentetate dimeglumine—Body temperature increased—Methotrexate—urinary bladder cancer	0.000117	0.000425	CcSEcCtD
Gadopentetate dimeglumine—Abdominal pain—Methotrexate—urinary bladder cancer	0.000117	0.000425	CcSEcCtD
Gadopentetate dimeglumine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000117	0.000424	CcSEcCtD
Gadopentetate dimeglumine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000115	0.000418	CcSEcCtD
Gadopentetate dimeglumine—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000114	0.000415	CcSEcCtD
Gadopentetate dimeglumine—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000114	0.000414	CcSEcCtD
Gadopentetate dimeglumine—Somnolence—Doxorubicin—urinary bladder cancer	0.000114	0.000414	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000113	0.000411	CcSEcCtD
Gadopentetate dimeglumine—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000111	0.000405	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000111	0.000402	CcSEcCtD
Gadopentetate dimeglumine—Fatigue—Doxorubicin—urinary bladder cancer	0.00011	0.000401	CcSEcCtD
Gadopentetate dimeglumine—Urticaria—Epirubicin—urinary bladder cancer	0.00011	0.0004	CcSEcCtD
Gadopentetate dimeglumine—Pain—Doxorubicin—urinary bladder cancer	0.000109	0.000398	CcSEcCtD
Gadopentetate dimeglumine—Constipation—Doxorubicin—urinary bladder cancer	0.000109	0.000398	CcSEcCtD
Gadopentetate dimeglumine—Abdominal pain—Epirubicin—urinary bladder cancer	0.000109	0.000398	CcSEcCtD
Gadopentetate dimeglumine—Body temperature increased—Epirubicin—urinary bladder cancer	0.000109	0.000398	CcSEcCtD
Gadopentetate dimeglumine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000109	0.000396	CcSEcCtD
Gadopentetate dimeglumine—Asthenia—Methotrexate—urinary bladder cancer	0.000106	0.000386	CcSEcCtD
Gadopentetate dimeglumine—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000106	0.000383	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000105	0.000381	CcSEcCtD
Gadopentetate dimeglumine—Pruritus—Methotrexate—urinary bladder cancer	0.000105	0.00038	CcSEcCtD
Gadopentetate dimeglumine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000102	0.000371	CcSEcCtD
Gadopentetate dimeglumine—Urticaria—Doxorubicin—urinary bladder cancer	0.000102	0.00037	CcSEcCtD
Gadopentetate dimeglumine—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000101	0.000368	CcSEcCtD
Gadopentetate dimeglumine—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000101	0.000368	CcSEcCtD
Gadopentetate dimeglumine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000101	0.000368	CcSEcCtD
Gadopentetate dimeglumine—Asthenia—Epirubicin—urinary bladder cancer	9.93e-05	0.000361	CcSEcCtD
Gadopentetate dimeglumine—Pruritus—Epirubicin—urinary bladder cancer	9.79e-05	0.000356	CcSEcCtD
Gadopentetate dimeglumine—Dizziness—Methotrexate—urinary bladder cancer	9.78e-05	0.000355	CcSEcCtD
Gadopentetate dimeglumine—Diarrhoea—Epirubicin—urinary bladder cancer	9.47e-05	0.000344	CcSEcCtD
Gadopentetate dimeglumine—Hypersensitivity—Doxorubicin—urinary bladder cancer	9.43e-05	0.000343	CcSEcCtD
Gadopentetate dimeglumine—Vomiting—Methotrexate—urinary bladder cancer	9.4e-05	0.000342	CcSEcCtD
Gadopentetate dimeglumine—Rash—Methotrexate—urinary bladder cancer	9.32e-05	0.000339	CcSEcCtD
Gadopentetate dimeglumine—Dermatitis—Methotrexate—urinary bladder cancer	9.31e-05	0.000339	CcSEcCtD
Gadopentetate dimeglumine—Headache—Methotrexate—urinary bladder cancer	9.26e-05	0.000337	CcSEcCtD
Gadopentetate dimeglumine—Asthenia—Doxorubicin—urinary bladder cancer	9.19e-05	0.000334	CcSEcCtD
Gadopentetate dimeglumine—Dizziness—Epirubicin—urinary bladder cancer	9.15e-05	0.000333	CcSEcCtD
Gadopentetate dimeglumine—Pruritus—Doxorubicin—urinary bladder cancer	9.06e-05	0.000329	CcSEcCtD
Gadopentetate dimeglumine—Vomiting—Epirubicin—urinary bladder cancer	8.8e-05	0.00032	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Methotrexate—urinary bladder cancer	8.78e-05	0.000319	CcSEcCtD
Gadopentetate dimeglumine—Diarrhoea—Doxorubicin—urinary bladder cancer	8.76e-05	0.000318	CcSEcCtD
Gadopentetate dimeglumine—Rash—Epirubicin—urinary bladder cancer	8.73e-05	0.000317	CcSEcCtD
Gadopentetate dimeglumine—Dermatitis—Epirubicin—urinary bladder cancer	8.72e-05	0.000317	CcSEcCtD
Gadopentetate dimeglumine—Headache—Epirubicin—urinary bladder cancer	8.67e-05	0.000315	CcSEcCtD
Gadopentetate dimeglumine—Dizziness—Doxorubicin—urinary bladder cancer	8.47e-05	0.000308	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Epirubicin—urinary bladder cancer	8.22e-05	0.000299	CcSEcCtD
Gadopentetate dimeglumine—Vomiting—Doxorubicin—urinary bladder cancer	8.14e-05	0.000296	CcSEcCtD
Gadopentetate dimeglumine—Rash—Doxorubicin—urinary bladder cancer	8.07e-05	0.000293	CcSEcCtD
Gadopentetate dimeglumine—Dermatitis—Doxorubicin—urinary bladder cancer	8.07e-05	0.000293	CcSEcCtD
Gadopentetate dimeglumine—Headache—Doxorubicin—urinary bladder cancer	8.02e-05	0.000292	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Doxorubicin—urinary bladder cancer	7.61e-05	0.000276	CcSEcCtD
